JPS59176264A - Physiologically active substance - Google Patents
Physiologically active substanceInfo
- Publication number
- JPS59176264A JPS59176264A JP58034492A JP3449283A JPS59176264A JP S59176264 A JPS59176264 A JP S59176264A JP 58034492 A JP58034492 A JP 58034492A JP 3449283 A JP3449283 A JP 3449283A JP S59176264 A JPS59176264 A JP S59176264A
- Authority
- JP
- Japan
- Prior art keywords
- chromatography
- group
- amino
- gizerocin
- acetyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013543 active substance Substances 0.000 title abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 9
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 7
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 5
- 125000003277 amino group Chemical group 0.000 claims description 7
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 19
- 238000004587 chromatography analysis Methods 0.000 abstract description 15
- 235000019733 Fish meal Nutrition 0.000 abstract description 14
- -1 amino, amino Chemical group 0.000 abstract description 14
- 239000004467 fishmeal Substances 0.000 abstract description 14
- 150000001875 compounds Chemical class 0.000 abstract description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 10
- 239000000741 silica gel Substances 0.000 abstract description 8
- 229910002027 silica gel Inorganic materials 0.000 abstract description 8
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 abstract description 6
- 230000002378 acidificating effect Effects 0.000 abstract description 6
- 241000287828 Gallus gallus Species 0.000 abstract description 5
- 241000269821 Scombridae Species 0.000 abstract description 4
- 239000003456 ion exchange resin Substances 0.000 abstract description 4
- 229920003303 ion-exchange polymer Polymers 0.000 abstract description 4
- 235000020640 mackerel Nutrition 0.000 abstract description 4
- 208000025865 Ulcer Diseases 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 239000011347 resin Substances 0.000 abstract description 3
- 229920005989 resin Polymers 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 241001125046 Sardina pilchardus Species 0.000 abstract description 2
- 230000003628 erosive effect Effects 0.000 abstract description 2
- 210000003205 muscle Anatomy 0.000 abstract description 2
- 235000019512 sardine Nutrition 0.000 abstract description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 2
- 241000251468 Actinopterygii Species 0.000 abstract 1
- LFNFNJYYTXESHV-UHFFFAOYSA-N L-Gizzerosine Chemical compound OC(=O)C(N)CCCCNCCC1=CNC=N1 LFNFNJYYTXESHV-UHFFFAOYSA-N 0.000 abstract 1
- 241000656145 Thyrsites atun Species 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 238000011981 development test Methods 0.000 abstract 1
- 235000019688 fish Nutrition 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 235000012054 meals Nutrition 0.000 abstract 1
- 235000020989 red meat Nutrition 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
- 238000010828 elution Methods 0.000 description 13
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 11
- 229910001868 water Inorganic materials 0.000 description 11
- 150000002500 ions Chemical class 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 229960001340 histamine Drugs 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 230000003387 muscular Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- ZKZNWRUUTQNYTH-UHFFFAOYSA-N 4-azidobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(N=[N+]=[N-])C=C1 ZKZNWRUUTQNYTH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000012445 acidic reagent Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010017865 Gastritis erosive Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241001290266 Sciaenops ocellatus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000269959 Xiphias gladius Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000002862 amidating effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- QRMKTNANRJCRCY-UHFFFAOYSA-N ethylammonium acetate Chemical compound CC[NH3+].CC([O-])=O QRMKTNANRJCRCY-UHFFFAOYSA-N 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000021335 sword fish Nutrition 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- AVBGNFCMKJOFIN-UHFFFAOYSA-N triethylammonium acetate Chemical compound CC(O)=O.CCN(CC)CC AVBGNFCMKJOFIN-UHFFFAOYSA-N 0.000 description 1
Abstract
Description
【発明の詳細な説明】 る。[Detailed description of the invention] Ru.
近年、ブロイラーに筋胃のびらん及び潰瘍な主機とする
疾病(以下、GEと記す。)が多発し、この疾病に関す
る研究が国内及び海外で盛んに行なわれている。そして
、このGEの発生とある種の魚粉の多給との間に相関関
係があることが海外で発表され、本発明者らもこのGE
の発生原因が飼料中に含まれる特定の魚粉にあることを
確認してその内容を既に発表した(日本家禽学会誌、第
17巻、第6号、第351〜357頁( 1 980年
)など)。In recent years, a disease mainly characterized by muscle gastric erosion and ulceration (hereinafter referred to as GE) has been occurring frequently in broilers, and research on this disease is being actively conducted both domestically and overseas. It has been announced overseas that there is a correlation between the occurrence of GE and the high intake of certain types of fishmeal, and the present inventors also
It has been confirmed that the cause of this outbreak is due to a specific fishmeal contained in feed, and the results have already been published (Journal of the Japanese Poultry Society, Vol. 17, No. 6, pp. 351-357 (1980), etc.) ).
しかしながら、その原因物質及び作用機序は依然として
不明であシ、本庁防止の適確な対応策も解決されていな
かった。However, the causative agent and mechanism of action are still unknown, and appropriate preventive measures have not yet been determined.
そこで、本発明者らはさらに研究を進め、試行錯誤を繰
返した結果、ついにこの原因物質を見出した。そして、
この物質は新規であシ、単体であってもあるいはペプチ
ド結合状態であっても、GE発現活性を示すことを見出
して、これに基いて本発明を完成するに至った。Therefore, the present inventors conducted further research and, after repeated trial and error, finally discovered the causative substance. and,
We have discovered that this substance is novel and exhibits GE expression activity whether alone or in a peptide-bound state, and based on this finding, we have completed the present invention.
本発明の化合物は一般式
(式中、R1は水素、低級アルキル基又はアセチル基を
表し、R2はOH基、低級アルコキシ基、アミン基、ア
ミノ酸残基又は被プチドを、そしてR3は水素、低級ア
ルキル基、アセチル基、アミノ酸残基又はベゾチドを表
す。)
で示される化合物である。The compound of the present invention has the general formula (wherein R1 represents hydrogen, a lower alkyl group, or an acetyl group, R2 represents an OH group, a lower alkoxy group, an amine group, an amino acid residue, or a peptide, and R3 represents hydrogen, a lower represents an alkyl group, acetyl group, amino acid residue, or bezotide).
この一般式で示される化合物のうち、魚粉を加水分解し
て得られたものは次式で示される2−アミノ−9−(4
−イミダゾリル)−7−アデツナン酸(本化合物をギゼ
ロシンと命名した。)である。Among the compounds represented by this general formula, those obtained by hydrolyzing fishmeal are 2-amino-9-(4
-imidazolyl)-7-adetunanoic acid (this compound was named gizerocin).
し
しかしながら、前記一般式に示す如く、この一般式のR
1又はR5の一方又は両方がメチル基、エチル基、イソ
プロピル基などのC1〜4の低級アルキル基あるいはア
セチル基であってもその化合物はGE発現活性を有し、
壕だ、R2がメトキシ基、エトキシ基、インロイシ基な
とのC7〜4の低級アルコキシ基あるいはアミノ基であ
ってもGE発現活性を有している。さらに、R2又はR
3の一方又は両方がアミノ酸残基又1l−lニー′−2
プチドであってもよい。アミノ酸残基のアミノ酸は天然
界に存するものであり、例えば、グリシン、アラニン、
ノぐリン、インロイシン、セリ、ン、フェニルアラニン
、ソロリン、トリプトファン、システィン、アスijラ
ギン、グルタミン酸、アルギニン、リシン、オルニチン
、ヒスチジンの如きものである。被プチドはこれらのア
ミノ酸の結合物であり、分子量は例えばオリコ+ベプチ
l゛程度であってもよく、10万程度であってもよい。However, as shown in the general formula above, R in this general formula
Even if one or both of 1 and R5 is a C1-4 lower alkyl group such as a methyl group, ethyl group, isopropyl group, or an acetyl group, the compound has GE expression activity,
Even if R2 is a C7-4 lower alkoxy group such as a methoxy group, ethoxy group, or inleuci group, or an amino group, it has GE expression activity. Furthermore, R2 or R
One or both of 3 is an amino acid residue or 1l-lnie'-2
It may be petite. Amino acid residues exist in nature, such as glycine, alanine,
These include nogulin, inleucine, serine, phenylalanine, soroline, tryptophan, cysteine, asijragine, glutamic acid, arginine, lysine, ornithine, and histidine. The peptide is a combination of these amino acids, and its molecular weight may be, for example, about Orico+Veptide, or about 100,000.
また、このペゾチドは糖蛋白、リポ蛋白などであっても
よい。Moreover, this pezotide may be a glycoprotein, a lipoprotein, or the like.
このような化合物は酸性部分又は塩基性部分が塩を形成
していてもよい。The acidic moiety or basic moiety of such a compound may form a salt.
本発明の化合物のうちギゼロシンは、GE発現活性を有
する魚粉、例えば鯖、鰯、秋刀魚、鮪などの赤身魚類の
魚粉から得ることができる。これらの魚粉を、例えば1
30°Cで5時間程度加熱処理することによってギゼロ
シンの収量を増すことができる。Among the compounds of the present invention, gizerocine can be obtained from fishmeal having GE expression activity, for example, fishmeal from red fish such as mackerel, sardine, swordfish, and tuna. For example, 1
The yield of Gizerocin can be increased by heat treatment at 30°C for about 5 hours.
魚粉をまず加水分解する。加水分解は蛋白質を加水分解
してアミノ酸を製造する常法に従えばよく、例えば3〜
6N程度の塩酸を加えて、80〜120℃で6〜48時
間程度加熱すればよい。このほか、プロテアーゼを用い
て酵素分解してもよいことはいうまでもない。Fishmeal is first hydrolyzed. Hydrolysis may be carried out in accordance with the conventional method of hydrolyzing proteins to produce amino acids, for example, 3-
What is necessary is to add about 6N hydrochloric acid and heat at 80 to 120°C for about 6 to 48 hours. In addition, it goes without saying that enzymatic decomposition using protease may be performed.
加水分解物からギゼロシンを分離するには、まず活性炭
、脱色樹脂等で色素及び芳香族化合物などを除去し、イ
オン交換樹脂を用いたクロマトグラフィーで非イオン物
質を除去するとともにギゼロシンとアミノ酸の分離を行
ない、さらにオクチルシリカケ8ルを用いたクロマトグ
ラフィー、セルロースを用いたクロマトグラフィー、オ
クタデシルシリカダルを用いたクロマトグラフィーを順
次行なえばよい。これらの方法のうち、特に活性炭ある
いは脱色樹脂による処理、強酸性イオン交換樹脂を用い
たクロマトグラフィー及びオクタデシルシリカゲルを用
いたクロマトグラフィーの精製効果が太きい。前二者の
工程で強塩基性物質のみが集められるが、この強塩基性
物質を相互分離してギゼロシンを単離する方法としてオ
クタデシルシリカゲルを用いたクロマトグラフィーは極
めて有効であり、ギゼロシンを単離しえたのはこのクロ
マトグラフィーに負うところが大きい。To separate gizerocin from the hydrolyzate, first remove pigments and aromatic compounds using activated carbon, decolorizing resin, etc., remove nonionic substances using chromatography using an ion exchange resin, and separate gizerocin and amino acids. Then, chromatography using octyl silica gel, chromatography using cellulose, and chromatography using octadecyl silica gel may be sequentially performed. Among these methods, treatment with activated carbon or decolorizing resin, chromatography using strongly acidic ion exchange resin, and chromatography using octadecyl silica gel have particularly great purification effects. Only strong basic substances are collected in the first two steps, but chromatography using octadecyl silica gel is extremely effective for separating these strong basic substances and isolating gizerocine. This achievement is largely due to chromatography.
これらのクロマトグラフィーにおいてギゼロシン区分を
検出する方法としては、GE発現活性を測定すればよい
わけであるが、簡便な方法として薄層クロマトグラフィ
ーがある。この方法の詳絹は実施例で述べる。In these chromatography methods, the gizerosin fraction can be detected by measuring GE expression activity, but thin layer chromatography is a simple method. Details of this method will be described in the Examples.
ギゼロシンはこのような天然物の加水分解でなく合成法
で取得できることもいうまでもない。Needless to say, Gizerocin can be obtained by a synthetic method rather than by hydrolysis of such natural products.
本発明の化合物のうち、一般式のR1又はR3の一方又
は両方が低級アルキル基であるものは、ギゼロシンを原
料として、アミノ基にアルキル基を導入する公知の方法
を用いて導入すればよく、例えば臭化メチル、臭化イソ
ゾロピルなどのノ・ロダン化物を作用させてアルキル化
し、必要によシ強酸性イオン交換樹脂を用いたクロマト
グラフィーなどで精製すればよい。Among the compounds of the present invention, those in which one or both of R1 and R3 in the general formula are lower alkyl groups may be introduced using a known method of introducing an alkyl group into an amino group using gizerocine as a raw material, For example, it may be alkylated by the action of a rhodanide such as methyl bromide or isozolopyl bromide, and if necessary purified by chromatography using a strongly acidic ion exchange resin.
また、一般式のR1又はR3の一方又は両方がアセチル
基であるものも、ギゼロシンに無水酢酸や塩化アセチル
などを作用させてアミン基をアセチル化し、必要によシ
蒸溜などで精製すればよい。Furthermore, in the case where one or both of R1 and R3 in the general formula is an acetyl group, the amine group may be acetylated by reacting acetic anhydride or acetyl chloride with gizerocin, and if necessary, the product may be purified by distillation or the like.
II2が低級アルコキシ基のものも、ギゼロシンを原料
としてカルボキシル基をエステル化する公知の方法、例
えば酸触媒の存在下でアルコールを作用させればよく、
R2がアミン基のものもギゼロシンを原料としてカルボ
キシル基をアミド化する公知の方法によって合成すれば
よい。In the case where II2 is a lower alkoxy group, it is sufficient to use a known method of esterifying a carboxyl group using gizerocin as a raw material, for example, by reacting with an alcohol in the presence of an acid catalyst.
Those in which R2 is an amine group may also be synthesized by a known method of amidating a carboxyl group using gizerocine as a raw material.
R2又はR3の一方又は両方がアミノ酸残基又は4プテ
ドのものは、アミノ酸相互をペプチド結合させる公知の
方法で合成してもよく、才だ、あるもの(は、GE発発
汗活性有する魚粉を部分加水分解し、DEAE−セルロ
ースを用いたクロマトグラフィーなどで分離取得するこ
ともできる。Those in which one or both of R2 and R3 are amino acid residues or 4-ptedones may be synthesized by a known method of bonding amino acids to each other through peptide bonds. It can also be separated and obtained by hydrolysis and chromatography using DEAE-cellulose.
本発明の化合物はブロイラーに対するGE発現活性は極
めて高く、例えば1日約50μgのギゼロシンをブロイ
ラーの雛に投与すると1週間以内にGEの症状を発症す
る。ヒスタミンを用いて同じ症状4発症させるだめKは
ヒスタミンを毎日約50〜投与する必要があるところか
ら、本発明の化合物のGE発現活性はヒスタミンよりけ
るかに強力である。The compound of the present invention has extremely high GE expression activity in broiler chickens. For example, when about 50 μg of gizerocin is administered to broiler chicks per day, GE symptoms will develop within one week. The GE expression activity of the compounds of the present invention is much stronger than that of histamine, since it is necessary to administer about 50 doses of histamine daily to induce the same symptoms using histamine.
本発明の化合物はGE発現テスト用の試薬としてGEを
撲滅する対策の研究上極めて有用であり、また、その生
理活性が極めて高いところから新たな医薬の開発が期待
できる。The compound of the present invention is extremely useful as a reagent for GE expression testing in research on countermeasures to eradicate GE, and since its physiological activity is extremely high, the development of new medicines can be expected.
以下の実施例におけるGE発現活性は次のように測定し
た。GE expression activity in the following examples was measured as follows.
市販飼料に一定量の飼料を加え、この飼料を3日令のブ
ロイラー雛4〜7羽に自由摂取させた。A fixed amount of feed was added to commercially available feed, and 4 to 7 3-day-old broiler chicks were given free access to this feed.
飼養温度は20℃とし、1週間後に解剖して筋胃粘膜の
傷害の程度を肉眼で観察した。飼養、中に死亡した雛も
その都度筋胃粘膜を観察した。The rearing temperature was 20°C, and the animals were dissected one week later and the degree of injury to the muscular gastric mucosa was visually observed. The muscular gastric mucosa of chicks that died during rearing was also observed.
筋胃粘膜の傷害の程度を、
GE強度O・・・ケラチンイド層に全く異常のみられな
いもの、および粗造化やびらんの程
度が極めて軽度なもの。The degree of injury to the muscular gastric mucosa is determined by GE intensity O: no abnormality is observed in the keratinoid layer, and the degree of roughening and erosion is extremely mild.
GEE度1・・・粗造化および、ひだの走行の乱れ等の
軽度の変化の認められるもの。GEE grade 1: Minor changes such as roughness and irregularities in the running of pleats are observed.
GEE度2・・・さらに明確なケラチンイド層の欠損が
認められるもの。GEE grade 2: A clear defect in the keratinoid layer is observed.
GE強度3・・・筋胃の潰瘍化が激しく穿孔によシ腹腔
まで貫通しているもの。GE intensity 3: Severe ulceration of the muscular stomach and perforation that has penetrated into the abdominal cavity.
の4段階に分け、各GE強度毎に、GE強度数×発症羽
数を求め、これを合算して得られた値をGEスコアとし
た。For each GE intensity, the number of GE intensity times the number of affected birds was calculated, and the value obtained by adding these together was used as the GE score.
対照試験は十対照と一対照について行ない、+対照はG
E活性を有する魚粉を、そして一対照はGE活性のない
魚粉を20%加えて試験を行なった。Control tests were conducted on 10 controls and 1 control, + control was G.
Tests were conducted with 20% fishmeal with E activity and one control with 20% fishmeal without GE activity.
実施例
1)加水分解
鯖の魚粉1 kl?に6N塩酸20Aを加え、110℃
で24時間加熱して加水分解した。Example 1) Hydrolyzed mackerel fishmeal 1 kl? Add 20A of 6N hydrochloric acid and heat to 110°C.
Hydrolysis was carried out by heating for 24 hours.
2)分離
この加水分解物に活性炭130.9を加えて、50〜6
0°Cで1時間攪拌した。活性炭を戸別し、p液を減圧
濃縮して塩酸及び水を除去した。2) Separation Add activated carbon 130.9 to this hydrolyzate to give 50 to 6
Stirred at 0°C for 1 hour. Activated carbon was distributed from house to house, and the p liquid was concentrated under reduced pressure to remove hydrochloric acid and water.
濃縮物に水を加え、この液を強酸性陽イオン交換樹脂ダ
ウエックス50WX8(H型)5Aに流した。Water was added to the concentrate, and this liquid was passed through a strongly acidic cation exchange resin DOWEX 50WX8 (H type) 5A.
このカラムに水13.0.5 N塩酸13A、2N塩酸
67〃、4N塩酸137を順次通液して段階的に溶離を
行ない、水、0.5 N塩酸及び2N塩酸で溶出される
流出液は13!づつ、そして4N塩酸で溶出される流出
液は45jづつ分画したところ、4N塩酸で溶出される
最初の両分にGE発現活性が認められた。各両分ごとに
7羽の雛を用いてGE発現活性を測定した結果のうち、
一部を下表2N塩酸溶出第3画分 217g 。Water 13A, 0.5N hydrochloric acid 13A, 2N hydrochloric acid 67〃, and 4N hydrochloric acid 137A were sequentially passed through this column for stepwise elution, and the effluent eluted with water, 0.5N hydrochloric acid, and 2N hydrochloric acid is 13! When the effluent eluted with 4N hydrochloric acid was fractionated into 45j fractions, GE expression activity was observed in the first two fractions eluted with 4N hydrochloric acid. Among the results of measuring GE expression activity using 7 chicks for each group,
A portion of the 3rd fraction eluted with 2N hydrochloric acid is shown in the table below, 217 g.
〃 第4画分 212 1
第5画分 198 2
4N塩酸溶出第1画分 174 12〃
第2画分 189 0〃 第3画分 2
06 l(+対照) 140 (
12)4N塩酸溶出第1両分を濃縮乾個し、この乾個
□物に水8mlを加えた。この液を弱酸性陽イオン交換
樹脂アンバーライ) IRCG−50(N−エチルモル
ホリン型)170mA!を充填したカラムに通液し、続
いてIMN−エチルモルホリン、2MN=エチルモルホ
リン、3Mアンモニア水各500m1順次通液して段階
的に溶出したところGE発現活性物質は3Mアンモニア
水で溶出された。各溶出画分ごとに4羽の雛を用いてG
E発現活性を測定し−た結果を下表に示す。4th fraction 212 1 5th fraction 198 2 4N hydrochloric acid elution 1st fraction 174 12
2nd fraction 189 0 3rd fraction 2
06 l (+control) 140 (
12) Concentrate and dry the first volume of 4N hydrochloric acid elution, and remove this dry volume.
□ Added 8 ml of water to the mixture. This solution is mixed with a weakly acidic cation exchange resin Amberly) IRCG-50 (N-ethylmorpholine type) 170mA! Then, 500 ml each of IMN-ethylmorpholine, 2MN-ethylmorpholine, and 3M aqueous ammonia were sequentially passed through the column for stepwise elution, and the GE-expressing active substance was eluted with the 3M aqueous ammonia. G using 4 chicks for each elution fraction
The results of measuring E expression activity are shown in the table below.
IMN−エチルモルホリン溶出画分 155,9
12MN−エチルモルホリン溶出画分 170,9
13Mアンモニア水溶出画分 138,9 1
1(十対照 134.9 8)
(一対照 162.!iJ 1)3Mアンモ
ニア水溶出画分を濃縮乾個後、約2mlのトリエチルア
ミン−酢酸緩衝液(pH7,0) K溶解した。この溶
液をオクチルシリカダル(Lichroprep RP
−8、メルク社製)15.7mJを充填したカラムに
流し、同緩衝液にイソプロパノールを0%、15%、3
0%、45%、6o係、75チ及び100チになるより
に加えた液を各100mA’づつ順次通液して段階的に
溶出したところGE発現活性物質は緩衝液のみの溶出画
分に見出された。各溶出画分ごとに4羽の雛を用いてG
E発現活性を測定した結果を下表に示す。IMN-ethylmorpholine elution fraction 155,9
12MN-ethylmorpholine elution fraction 170.9
13M ammonia water elution fraction 138,9 1
1 (10 controls 134.9 8) (1 control 162.!iJ 1) The 3M ammonia water elution fraction was concentrated to dryness and then dissolved in about 2 ml of triethylamine-acetate buffer (pH 7.0). This solution was mixed with octyl silica dal (Lichroprep RP).
-8, manufactured by Merck & Co., Ltd.) was applied to a column packed with 15.7 mJ, and the same buffer solution was mixed with isopropanol at 0%, 15%, and 3.
When the solutions added at 0%, 45%, 6o, 75 and 100% were sequentially eluted at 100mA each, the GE-expressing active substance was found in the elution fraction of the buffer only. discovered. G using 4 chicks for each elution fraction
The results of measuring E expression activity are shown in the table below.
イングロパノール 0チ 125,9 131
5チ 168 3
30% 175 1
45% 179 0
60チ 178 1
75% 154 1
100% 181 3
(+対照 140 13
(=対照 1633
セルロースを吸着剤とするクロマトグラムシート(商品
名、イーストマンコダック社製)に各溶出画分をスポツ
ティングし、イングロパノール−28%NH40)T−
H2O(16: 3.5 : 4 )の展開溶媒で展開
して薄層クロマトグラフィーを行ない、ジアゾスルファ
ニル酸試薬で発色したところ、GE発現活性物質のRf
値は0.58であった。Inglopanol 0chi 125,9 131
5chi 168 3 30% 175 1 45% 179 0 60chi 178 1 75% 154 1 100% 181 3 (+ control 140 13 (= control 1633 Chromatogram sheet with cellulose as adsorbent (product name, Eastman Kodak Company) Each eluted fraction was spotted on a tube made by Ingropanol-28% NH40)T-
Thin layer chromatography was performed by developing with a developing solvent of H2O (16: 3.5: 4), and color development with a diazosulfanilic acid reagent revealed that the Rf of the GE-expressing active substance
The value was 0.58.
緩衝液のみの溶出画分を減圧乾個後少量の水を加えて溶
解した。この液を、予めイソプロパノ−ルー28係NH
40H−H2O(16:1:4)の溶媒で平衡化したセ
ルロースカラムに(充填i24.0m1)流し、同じ溶
媒で展開して流出液を81nlごとに分画して取得した
。この各両分を前記の薄層クロマトグラフィーで分析し
たところ、カラム体積の0.24〜040倍のところの
両分に活性物質が溶出されてきた。この活性画分のうち
、最前部の両分及び最後部の両分には他のジアゾスルフ
ァニル酸試薬発色物質が混入していることをこの薄層ク
ロマトグラフィーで確認していたので、この薄層クロマ
トグラフィーの手法でこれらの発色物質を分離除去した
。The elution fraction containing only the buffer solution was dried under reduced pressure and dissolved by adding a small amount of water. Add this solution in advance to isopropanol-28 NH
It was applied to a cellulose column equilibrated with a solvent of 40H-H2O (16:1:4) (packing i: 24.0 ml), developed with the same solvent, and the effluent was fractionated into 81 nl portions. When both of these fractions were analyzed by the thin layer chromatography described above, the active substance was eluted in both fractions at 0.24 to 0.40 times the column volume. Of this active fraction, we had confirmed through thin layer chromatography that other diazosulfanilic acid reagent color-forming substances were mixed in both the frontmost fraction and the last fraction. These colored substances were separated and removed using chromatography.
最終段階の精製はオクタデシルシリカゲルを用いた逆層
分配高速液体クロマトグラフィーで行なった。まず、前
工程の活性画分を集めて減圧乾個し、少量の0.05M
)リエチルアンモニウムー酢酸緩衝液(pH7,0)で
溶解した。この液を一回魚粉50g相当分オクタデシル
シリカダルであるヌクレオシルNC,−18(商品名、
ナーグル社製)12.6rnlを充填した8X250誦
のカラムに3 m/:/minの速度で流し、続いて同
じ緩衝液を同じ速度で流して溶離展開したところ図面に
示すクロマトグラムが得られた。このクロマトグラムの
各ピークに示した数字の画分ごとに5羽の雛を用いてG
E発現活性を測定した結果を下表に示す。The final stage of purification was performed by reverse phase partition high performance liquid chromatography using octadecyl silica gel. First, the active fractions from the previous step were collected and dried under reduced pressure, and a small amount of 0.05M
) Dissolved in ethyl ammonium-acetate buffer (pH 7.0). Dispense this solution at a time equivalent to 50g of fishmeal into Nucleosil NC,-18 (trade name,
When the solution was run at a rate of 3 m/:/min through an 8 x 250 column packed with 12.6 rnl (manufactured by Nagle) and then the same buffer was run at the same rate for elution development, the chromatogram shown in the figure was obtained. . Using five chicks, G
The results of measuring E expression activity are shown in the table below.
1 140g 2 2 95 12 3 134 1 4 1、42 0 5 131 1 6 123 0 (+対照 114 8 ) (一対照 154 0 ) 以上の精製工程の結果を下表にまとめて示す。1 140g 2 2 95 12 3 134 1 4 1, 42 0 5 131 1 6 123 0 (+Control 114 8) (One comparison 154 0) The results of the above purification steps are summarized in the table below.
魚 粉 1 kg440 U
2300IncJ/Uダウエツクス50WX8
Fl 380 13アンバーライトIRC
G−5012g 110 11オクチルシリカ
ゲル 0.29 55 3.6セル
ロース 10■ 5002オクタデシルシ
リカゲル 0.7m9 28 0.03
*11羽の雛[7日以内にGEを発現させる活性を1単
位とした。Fish meal 1 kg440U
2300IncJ/U Dowex 50WX8
Fl 380 13 Amber Light IRC
G-5012g 110 11 octyl silica gel 0.29 55 3.6 Cellulose 10■ 5002 octadecyl silica gel 0.7m9 28 0.03
*11 chicks [The activity to express GE within 7 days was defined as 1 unit.
この第2ピークの両分を吸着剤としてセルロースとシリ
カダルを用い、展開溶媒にはインゾロパノール−28%
NH40H−H20(16:3.5:4)、n−ブタノ
ール−HCoOH−H20(17: 4 : 5 )及
びインゾロパノールーHCOOI(−H20(16:5
.5 :6)の3種を用いて合計6種の薄層クロマルブ
ラフィーを行々い、ジアゾスルファニル酸試薬及びフル
オレスカミンの両方で発色させたところ、いずれも唯一
のスポット金示したのでこのものは単一物であることが
判明し、このものをギゼロシンと命名した。Cellulose and silicadal were used as adsorbents for both of this second peak, and inzolopanol-28% was used as the developing solvent.
NH40H-H20 (16:3.5:4), n-butanol-HCoOH-H20 (17:4:5) and inzolopanol-HCOOI (-H20 (16:5)
.. A total of 6 types of thin layer chromaburography were performed using 3 types of 5:6), and when color was developed with both diazosulfanilic acid reagent and fluorescamine, only one spot of gold was shown in each case. The object turned out to be a single object, and was named Gizeroshin.
ギゼロシン水溶液のUV吸収を測定したところ、λmユ
Xは209 nmにあった。When the UV absorption of the aqueous Gizerocin solution was measured, λm was found to be 209 nm.
3)構造決定
ギゼロシンヒE/Dマススペクトルを測定したところ、
m/Z 241 (M+H”)、263 (M+Na”
)及び279 (M+K”)の3つのピークが観察され
た。その結果、ギゼロシンの分子量は240であること
が判非した。3) Structure determination Gizerosinch E/D mass spectrum was measured.
m/Z 241 (M+H”), 263 (M+Na”
) and 279 (M+K'') were observed. As a result, it was determined that the molecular weight of Gizerocin was 240.
ギゼロシンに無水酢酸及びメタノールを加え、室温で4
8時間反応させた。このギゼロシン誘導体をEI嵩高分
解能マススペクトル法測定した結果、mA338.19
518(C16H2604N4、理論値338.195
40)の分子イオンぎ−りが観察された。Add acetic anhydride and methanol to Gizerocin and stir at room temperature for 4 hours.
The reaction was allowed to proceed for 8 hours. As a result of measuring this Gizerocin derivative using EI bulk resolution mass spectrometry, mA was 338.19.
518 (C16H2604N4, theoretical value 338.195
40) was observed.
これにより、ギゼロシンにはアセチル化しうるアミノ基
又はイミノ基が2個とカルボキシル基1個があり、かつ
ギゼロシンの分子式がC11H2oO2N4であること
が判明した。This revealed that Gizerocin has two amino or imino groups and one carboxyl group that can be acetylated, and that the molecular formula of Gizerocin is C11H2oO2N4.
ギゼロシンを重水に溶かして400 MHz ’H−N
MRスペクトルを測定したところイミダゾール環に由来
するδH732と8.43の2つのプロトンのピークが
観測された。また、スピンデカップリングにより、分子
内に−N−(CH2)4−CH−N−と−C−cT(2
−CH2−N−のあることが判明し、分子内にリジンと
ヒスタミン残基のあることが示唆された。そこで、リジ
ン及びヒスタミンをギゼロシンと同じ条件で400MT
(z ’H−NMRスペクトルを測定して、ギゼロシン
のスペクトルと比較して、ギゼロシンはこれらの残基を
有していることを確認した。さらに、この比較によって
リジンのε−メチレンはイミダゾール環のNと結合して
おらず、また、ヒスタミンのアミン基のメチレンはアミ
ド結合のものではないことが示唆された。Dissolve Gizerocin in heavy water and generate 400 MHz 'H-N
When the MR spectrum was measured, two proton peaks at δH732 and 8.43 derived from the imidazole ring were observed. In addition, due to spin decoupling, -N-(CH2)4-CH-N- and -C-cT(2
It was found that -CH2-N- was present, suggesting that there were lysine and histamine residues in the molecule. Therefore, 400MT of lysine and histamine were added under the same conditions as Gizerocin.
(Z'H-NMR spectrum was measured and compared with the spectrum of Gizerocine, confirming that Gizerocine has these residues. Furthermore, this comparison shows that the ε-methylene of lysine is the same as that of the imidazole ring. It was suggested that the methylene of the amine group of histamine was not bonded to N and was not an amide bond.
さらに、前記のギゼロシンの誘導体をEIマススペクト
ルのリンクトスカン法で測定した結果、m/Z 338
の親イオンに直接由来するm7z 乏a−g及び245
のフラグメントイオンのピークが観察された。そして、
高分解能マスス被りトロメトリーによって、m/Z 2
45のフラグメントイオンの分子式はC11H21N2
04(実測値245.152]3、理論値245.15
0’12)であることが判明した。このフラグメントイ
オンは親イオンからイミダゾール部分が脱離したものと
考えられる。また、高分解能マススペクトロメトリーに
よってm/Z 208のフラグメントイオンの分子式は
C11H8N30(実測値208.14472、理論値
208.14498)であることが判明した。このフラ
グメントイオンは親イオンから)ic (NI(COC
H3)COOCH6が脱離したものと考えられる。その
結果、ギゼロシンはその分子内に一置換のイミダゾール
環とα−アミノカルデキシル基があると考えられる。Furthermore, as a result of measuring the above-mentioned Gizerocin derivative by the linked scan method of EI mass spectrum, m/Z 338
m7z-poor a-g and 245 derived directly from the parent ion of
A fragment ion peak was observed. and,
By high-resolution mass coverage trometry, m/Z 2
The molecular formula of the fragment ion of 45 is C11H21N2
04 (actual value 245.152) 3, theoretical value 245.15
0'12). This fragment ion is considered to be the imidazole moiety removed from the parent ion. Further, high-resolution mass spectrometry revealed that the molecular formula of the fragment ion with m/Z 208 was C11H8N30 (actual value 208.14472, theoretical value 208.14498). This fragment ion is derived from the parent ion)ic (NI(COC
H3) It is thought that COOCH6 was desorbed. As a result, Gizerocin is thought to have a monosubstituted imidazole ring and an α-aminocardexyl group in its molecule.
以上の結果、ギゼロシンの構造を と決定した。As a result of the above, the structure of Gizerocine is It was decided.
ギゼロシンがこの構造を有していることはさらに、この
ものを化学合成し、得られた合成品の’H−NMRス4
クトルが、魚粉から得られたギゼロシンのものと同一で
あることによっても確認された。この合成ギゼロシンは
やはり強いGE発現活性を示した。The fact that Gizerocin has this structure is further evidenced by the 'H-NMR spectrum of the synthesized product obtained by chemically synthesizing it.
It was also confirmed that the cuttle was identical to that of gizerocin obtained from fishmeal. This synthetic gizerocin also showed strong GE expression activity.
図面は魚粉の加水分解物から本発明の化合物を取得する
精製工程において、オクタデシルシリカダルを用いてク
ロマトグラフィーを行なった結果を示すものである。
特許出願人 伊藤忠飼料株式会社
代理人 弁理士田中政浩The drawing shows the results of chromatography using octadecyl silica dal in the purification process for obtaining the compound of the present invention from fishmeal hydrolyzate. Patent applicant: Itochu Feed Co., Ltd. Representative: Masahiro Tanaka, patent attorney
Claims (1)
表し、R2はOH基、低級アルコキシ基、アミン基、ア
ミノ酸残基又はペプチドを、そしてR3は水素、低級ア
ルキル基、アセチル基、アミノ酸残基又は及プチドを表
す。) で示される化合物[Claims] General formula (wherein R1 represents hydrogen, a lower alkyl group, or an acetyl group, R2 represents an OH group, a lower alkoxy group, an amine group, an amino acid residue, or a peptide, and R3 represents hydrogen, a lower Represents an alkyl group, acetyl group, amino acid residue or peptide)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58034492A JPS59176264A (en) | 1983-03-04 | 1983-03-04 | Physiologically active substance |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58034492A JPS59176264A (en) | 1983-03-04 | 1983-03-04 | Physiologically active substance |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS59176264A true JPS59176264A (en) | 1984-10-05 |
JPS6241665B2 JPS6241665B2 (en) | 1987-09-03 |
Family
ID=12415740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP58034492A Granted JPS59176264A (en) | 1983-03-04 | 1983-03-04 | Physiologically active substance |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS59176264A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7179491B1 (en) | 1999-01-29 | 2007-02-20 | Ted Mag | Process of converting rendered triglyceride oil from marine sources into bland, stable oil |
-
1983
- 1983-03-04 JP JP58034492A patent/JPS59176264A/en active Granted
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7179491B1 (en) | 1999-01-29 | 2007-02-20 | Ted Mag | Process of converting rendered triglyceride oil from marine sources into bland, stable oil |
Also Published As
Publication number | Publication date |
---|---|
JPS6241665B2 (en) | 1987-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4329281A (en) | Hapten compositions | |
Francis et al. | Biosynthetic pathway of desmosines in elastin | |
Barton et al. | Solid-phase synthesis of selectively protected peptides for use as building units in the solid-phase synthesis of large molecules | |
EP0506748B1 (en) | Amino acids, peptides or derivatives thereof coupled to fats | |
Keith et al. | Synthesis of L-2-amino-4-methoxy-trans-but-3-enoic acid | |
Morris et al. | The isolation and characterization of γ-l-glutamyl-l-tyrosine and γ-l-glutamyl-l-phenylalanine from soybeans | |
JPH07188282A (en) | Novel tripeptide, its production and hypotensor containing the same as an active ingredient | |
US6274747B1 (en) | Polyunsaturated fatty acid derivatives and their use | |
Mitchell | Structure: bacterial | |
EP0179324A2 (en) | Anti-bacterial composition | |
JPS59176264A (en) | Physiologically active substance | |
KOTAKI et al. | Acid and Alkaline Degradation of the TNP-Amino Acids and-Peptides | |
MORISHIMA et al. | SYNTHESIS OF 4-AMINO-3 HYDROXY-6-METHYLHEPTANOIG ACID, AN AMINE COMPONENT OF PEPSTATIN | |
US4412988A (en) | Hexapeptides | |
Shevchenko et al. | Proteolysis of simple glyprolines by leucine aminopeptidase and enzymes from nasal mucus, brain membranes, and blood of rats | |
US3846398A (en) | Method for controlled stepwise synthesis of polypeptides utilizing n-thiocarboxy anhydrides of amino acids as reagents | |
JPH01226898A (en) | Novel peptide and hypotensive agent containing said peptide | |
JPH04169597A (en) | Purification of taurine-conjugation-type bile acid | |
PL167043B1 (en) | Method of obtaining novel monomer of 3-rd order butoxycarbonyl-l-thyrosipeptide glicane and its derivative labelled with 125 j | |
JPS6230748A (en) | L-aminocarboxylic acid amide of substituted amine | |
Lannom et al. | 13C nmr study of the structure and the metal ion binding sites of neuropeptides composed of L‐Asp and L‐Glu | |
Bunyatyan et al. | Synthesis and some Pharmacological Properties of an Immunoactive Lysine-Containing Tetrapeptide | |
JPH08225593A (en) | Novel tetrapeptide, pentapeptide and angiotensin-transferase inhibitor | |
Silver et al. | Nature of the amino-enzyme intermediate in pepsin-catalyzed reactions | |
EP1161436B1 (en) | Polyunsaturated fatty acid derivatives and their use in the treatment of cancer |